Ionis says partner GSK’s bepirovirsen met primary endpoints in two Phase 3 chronic hepatitis B trials

 

• Ionis reports bepirovirsen achieved unprecedented functional cure rates in two Phase 3 chronic hepatitis B studies
• Positive Phase 3 data reinforces bepirovirsen’s prospects under priority regulatory review, according to Ionis
• Ionis highlights bepirovirsen’s success as supportive of the company’s future royalty potential from the program

https://finviz.com/stock?t=IONS&ty=c&ta=1&p=d